Arexvy®
Company
GlaxoSmithKline
Use
Prevention of respiratory syncytial virus (RSV) in adults 60+.
Features
First RSV vaccine for older adults, based on recombinant subunit prefusion RSV F glycoprotein antigen.
HHS Institute/Agency
NIAID
Inventor(s)
Kwong, P. et al.
Year
2023
